Published in Transplant Weekly, March 26th, 2000
The treatment of P190(BCR-ABL+) acute lymphoblastic leukemia (ALL) patients remains problematic. One treatment possibility is to use biologic response modifiers such as (alpha)-interferon ((alpha)-IFN), which is known to be active in chronic myeloid leukemia (CML), noted G. Visani and colleagues.
They used (alpha)-IFN to treat 10 adult p190(BCR-ABL+) ALL patients (eight newly diagnosed; two in first relapse) ("Alpha-interferon improves...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Transplant Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.